Two medications have reshaped the conversation around weight loss over the past few years: semaglutide and tirzepatide. Both are weekly injections. Both suppress appetite, help regulate blood sugar, and have produced results that would have seemed implausible a decade ago. And both are now widely available through telehealth.
But they are not the same drug — and there's a real difference in how much weight people tend to lose on each one. Here's what the research shows.
Two Drugs, One Key Difference
Semaglutide works by mimicking a hormone your gut releases after you eat. That hormone — called GLP-1 — tells your brain you're full and slows digestion. The result: you eat less, feel satisfied sooner, and lose weight over time.
Tirzepatide does all of that, and then some. It also targets a second gut hormone called GIP, which stimulates insulin release in response to food (blood sugar). Think of it as two levers instead of one. That dual mechanism is the core reason researchers expected tirzepatide to outperform semaglutide on weight loss — and the data has confirmed it.
What the Studies Show
The first head-to-head comparison to date is the SURMOUNT-5 trial, published in the New England Journal of Medicine. This was a head-to-head randomized controlled trial — the gold standard in medical research — where participants were assigned to either tirzepatide or semaglutide and followed for 72 weeks. The result: people on tirzepatide lost an average of 20% of their body weight, compared to 14% for semaglutide. For someone starting at 250 pounds, that's the difference between losing 35 pounds versus 50.
The gap holds up in larger real-world analyses too. A 2024 study in JAMA Internal Medicine looked at nearly 18,400 patients and found that people on tirzepatide were far more likely to hit the kinds of milestones that translate into real health changes — losing 10%, 15%, or more of their starting weight. At each threshold, tirzepatide came out ahead by a wide margin.
Over a longer horizon, the picture is similar. A two-year analysis published in PNAS Nexus followed more than 20,000 patients and found that tirzepatide users lost nearly 15% of their body weight on average, compared to 11% for semaglutide — and the gap didn't close over time. Among the highest responders, roughly twice as many people on tirzepatide lost 20% or more of their starting weight.
These findings are consistent across study types: controlled trials, real-world cohorts, and a 2025 systematic review that pooled data from more than 140,000 patients. The advantage for tirzepatide shows up reliably, which is what makes the evidence compelling.
What About Side Effects?
Both medications can cause nausea, vomiting, and constipation — especially early on, while your body adjusts to the drug. While the majority of patients report light side effects, it’s the most common concern patients raise, and a legitimate one.
Here's the part that surprises most people: the two-year PNAS Nexus study found that tirzepatide users actually reported lower rates of GI side effects than semaglutide users. Nausea, vomiting, and constipation were all less common in the tirzepatide group. The SURMOUNT-5 trial found that GI side effects were similar between the two groups — mostly mild to moderate and most common during the early dose escalation period.
In other words, the medication that tends to produce more weight loss doesn't appear to be harder on your stomach. For many patients, that's a meaningful data point.
So Which One Should You Choose?
The research consistently points in the same direction: tirzepatide produces more weight loss, reaches more patients' goals, and does so without a worse side effect profile.
That said, there are real-world factors that matter just as much as clinical data. Semaglutide has been on the market longer, is available in both injectable and oral forms, and has an extensive body of evidence in people with heart disease and type 2 diabetes. Cost and insurance coverage also play a significant role — tirzepatide typically carries a higher list price, and not everyone has the same coverage.
The right choice also depends on how your body responds. Some people do better on one medication than the other, and individual variation is real. That's why this conversation belongs with a clinician who can look at your full picture — not just a data table.
The Bottom Line
If your goal is to lose as much weight as possible with medication support, the evidence favors tirzepatide. It's not a small difference — across multiple large studies, patients on tirzepatide have lost meaningfully more weight, and more of them have reached the thresholds that change health outcomes.
But the best medication is the one that fits your body, your life, and your budget — and that you can stay on long enough to see results. If you want help figuring out which one makes sense for you, a SteadiCare provider can walk through your options and put together a plan that fits.